http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2014124184-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-436 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 |
| filingDate | 2012-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2014124184-A |
| titleOfInvention | COMBINATION OF PHOSPHOINOSITIDE-3-KINASE INHIBITOR AND MODULATOR OF THE WAY OF JANUS-KINASE 2 - SIGNAL CONDUCTOR AND TRANSCRIPTION ACTIVATOR 5 |
| abstract | 1. A combination for use as a medicament, comprising (a) a phosphoinositide 3-kinase inhibitor compound (PI3K) and (b) a compound that modulates the pathway of Janus kinase 2 (JAK2), a signal conductor and transcription activator 5 (STAT5) ), the active ingredients being present in each case in free form or in the form of its pharmaceutically acceptable salt or any hydrate, and optionally at least one pharmaceutically acceptable carrier; for simultaneous, separate or sequential use. 2. The combination of claim 1, wherein the phosphoinositide-3-kinase inhibitor compound is selected from the group consisting of compound A, compound B, compound C, rapamycin, temsirolimus, everolimus, temsirolimus, ridaforolimus, MK-8669, sirolimus, zotarolimus and biolimus. 3. The combination of claim 1 or 2, wherein the compound that modulates the JAK2-STAT5 pathway is selected from the group consisting of lestartinib, ruksolitinib, SB1518, CYT387, LY3009104, INC424, LY2784544, BMS-911543, NS-018, TG101348, compounds D compounds E, compounds F, compounds G, compounds H and compounds I.4. The combination of claim 1, wherein the phosphoinositide-3-kinase inhibitor compound and / or the compound that modulates the JAK2-STAT5 pathway are siRNA. The combination of claim 1, wherein the compound that modulates the JAK2-STAT5 pathway inhibits the secretion of interleukin 8 (IL8). 6. The combination of claim 1, wherein the phosphoinositide 3-kinase inhibitor is compound A.7. The combination of claim 1, wherein the phosphoinositide 3-kinase inhibitor is compound C.8. The combination of claim 1, wherein the phosphoinositide 3-kinase inhibitor is everolimus. The combination of claim 1 for use in the treatment of a proliferative disease. 10. Combination � |
| priorityDate | 2011-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 66.